Global News

Bill Gates, Tenaya Capital invest in ResearchGate

Friday, June 7, 2013 01:58 PM

ResearchGate, a professional network for scientists, has a new investment from Bill Gates and Tenaya Capital with participation from Dragoneer Investment Group, Thrive Capital and the company's existing investors Benchmark and Founders Fund.

More... »

Impax Laboratories to cut workforce

Friday, June 7, 2013 01:57 PM

Impax Laboratories, a technology-based specialty pharmaceutical company, will implement a reduction in its workforce as a part of efforts to streamline its operations in response to the need to reduce expenses and adapt to changing market conditions. The reduction primarily affects manufacturing operations and is intended to reduce Impax's cost structure and scale the organization appropriately for its current needs.

More... »

CytomX, Pfizer collaborate to develop and commercialize in oncology

Friday, June 7, 2013 01:54 PM

CytomX Therapeutics, a biotechnology company developing a new generation of targeted antibody therapeutics, has entered into a global collaboration with Pfizer to develop and commercialize multiple Probody-Drug Conjugates (PDCs).

More... »

Johnson & Johnson opens London Innovation Center

Friday, June 7, 2013 01:49 PM

Johnson & Johnson has opened the J&J Innovation Center in London, one of four regional hubs being established this year.  The goal of the Innovation Center is to accelerate early stage science and advance the development of new healthcare solutions.

More... »

Clinverse launches ClinSpend

Friday, June 7, 2013 01:44 PM

Clinverse, a global technology and financial services company for clinical trials, has introduced its ClinSpend solution, designed to meet the reporting requirements to the Center for Medicare and Medicaid Services (CMS) for the federally mandated Sunshine Act, now called Open Payments, providing greater transparency around the financial relationships of manufacturers, physicians and teaching hospitals. 

More... »

Neurelis, Biotie Therapies partners, with acquisition option

Thursday, June 6, 2013 01:46 PM

Pharmaceutical company Neurelis has signed an agreement with Biotie Therapies, a specialized drug development company, to develop intranasal diazepam (NRL-1) and provide Biotie with the exclusive option, but not the obligation, to acquire all outstanding shares of Neurelis.

More... »

MorphoSys, GSK ink license agreement

Thursday, June 6, 2013 01:35 PM

Pharmaceutical developer MorphoSys has entered into a global agreement with GlaxoSmithKline to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody against GM-CSF, which has concluded phase I/II development in mild to moderate rheumatoid arthritis.

More... »

Fujifilm, Dr. Reddy's call off joint venture for generic drugs in Japan

Wednesday, June 5, 2013 01:37 PM

Healthcare company Fujifilm and India-based global pharmaceutical company Dr. Reddy's Laboratories have decided to terminate the Memorandum of Understanding (MoU) to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan.

More... »

Japan screening massive drug compound libraries for new treatments

Wednesday, June 5, 2013 01:32 PM

The Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership focused on Japanese R&D related to infectious disease, will make a series of agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis and other afflictions.

More... »

Sanofi discontinues development of two investigational compounds

Tuesday, June 4, 2013 10:00 AM

Sanofi, a global healthcare company, announced topline results of two phase III clinical studies of investigational compounds iniparib and otamixaban and, as a result, has announced it will discontinue both programs.

More... »